MIRA Pharmaceuticals consolidates global rights for pipeline candidates MIRA-55 and SKNY-1

MIRA Pharmaceuticals (NASDAQ:MIRA) announced that it has executed an Amended and Restated Exclusive License Agreement with MIRALOGX.

This strategic move grants MIRA worldwide exclusive rights to its lead candidates, MIRA-55 and SKNY-1, further solidifying the company's control over the development and commercialization of its proprietary therapeutic portfolio.

The agreement consolidates critical operational functions, including global development, commercialization, sublicensing, and intellectual property enforcement.

Notably, the scope of this consolidation extends to the company’s broader pipeline, including the neuropathic pain candidate Ketamir-2.

According to the company, these amendments streamline administrative oversight and operational clarity without materially altering the core economic terms of the original partnership.

By centralizing these rights, MIRA aims to accelerate the advancement of its drug candidates through global regulatory and clinical processes.